OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights
02 nov. 2017 16h05 HE
|
OncoMed Pharmaceuticals, Inc.
Q3 Cash Balance of $113.6M – Cash through Q3 2019 Continued progress on the advancement of key clinical programs including GITRL-Fc Phase 1 initiation Management to Host Conference Call/Webcast this...